Ernexa Therapeutics (ERNA) vs 60 Degrees Pharmaceuticals (SXTP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ernexa Therapeutics is the larger company by market cap ($2.3 million vs $2.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ERNA | SXTP |
|---|---|---|
| Share price | $1.36 | $0.4682 |
| Market cap | $2.30M | $2.10M |
| 1-day change | -16.56% | -6.36% |
| EPS (TTM) | $-11.22 | $-5.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.01M |
| Revenue growth (YoY) | — | +65.49% |
| Net income (latest FY) | $-14.08M | $-7.37M |
| Gross margin | — | 22.26% |
| Operating margin | — | -771.64% |
| Net margin | — | -732.51% |
| 52-week high | $37.50 | $8.62 |
| 52-week low | $1.35 | $0.46 |
| Distance from 52-week high | -96.37% | -94.57% |
| Analyst consensus | none | none |
| Avg. price target upside | +2105.88% | +690.26% |
| Average volume | 43.90K | 407.29K |
| Shares outstanding | 1.69M | 4.48M |
| Employees | 5 | 3 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ernexa Therapeutics
ERNA stock →Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About 60 Degrees Pharmaceuticals
SXTP stock →60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
ERNA vs SXTP FAQ
Which is bigger, Ernexa Therapeutics or 60 Degrees Pharmaceuticals?
Ernexa Therapeutics (ERNA) is larger, with a market capitalization of $2.30M compared with $2.10M for 60 Degrees Pharmaceuticals (SXTP).
Are Ernexa Therapeutics and 60 Degrees Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.